Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
December 07, 2022 16:01 ET
|
Design Therapeutics, Inc.
DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia Second GeneTACTM Development Candidate, DT-168, Selected for the Treatment...
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
November 03, 2022 16:05 ET
|
Design Therapeutics, Inc.
Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022 Dosing Initiated in the Multiple-Ascending Dose Phase 1 Trial of DT-216;...
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
October 17, 2022 16:05 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
September 22, 2022 06:30 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
August 08, 2022 16:05 ET
|
Design Therapeutics, Inc.
Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022 Strong Financial Position with $359.4 Million in Cash and Securities to Support Multi-Year Operating...
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
August 03, 2022 06:30 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022 06:30 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
May 09, 2022 16:05 ET
|
Design Therapeutics, Inc.
Clinical Execution of Lead GeneTAC™ Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of Friedreich Ataxia Robust Research Pipeline of GeneTAC™ Candidates, with Promising New...
Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia
March 30, 2022 06:30 ET
|
Design Therapeutics, Inc.
Topline Data from Phase 1 Trial Expected in the Second Half of 2022 DT-216 Granted FDA Fast Track Designation for Patients with Friedreich Ataxia CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE)...
Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
March 10, 2022 16:02 ET
|
Design Therapeutics, Inc.
Phase 1 Trial of DT-216, a Novel FA GeneTAC™ Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel GeneTAC™ Small Molecules for the...